Fioriti L, Wijesekara N, Argyrousi EK, et al. Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease. Alzheimers Dement. 2025;21(3):e70030. doi:10.1002/alz.70030
The article originally listed an individual in the acknowledgements who requested to be removed. That name has been removed from the acknowledgements section of the published article. The Acknowledgement section now reads as follows:
ACKNOWLEDGMENTS
The authors thank the technical contributions by Ms. Kathy Ha, Ms. Ling Wu, and Sara Palacino for technical support. This work was supported by the Canadian Institutes of Health Research (PJT‐173497 to P.E.F.), the Weston Brain Institute (TR192065 to P.E.F.), the Alzheimer's Association (AARG 17‐505136 to L.F.), National Institutes of Health (NIH‐NINDS R01NS110024 and R01NS049442 to O.A., NIH R01NS134902 to L.F.), the Japanese Society for the Promotion of Science (JSPS) for a Fund for the Promotion of Joint International Research (Fostering Joint International Research) (17KK0197 to S.M.), and Grant‐in‐Aid for Scientific Research (C) (21K06759 to S.M.).